Evidence map›Paper›PMID 39051402›Full record

ArticleInternational journal of neonatal screening2024

Evaluation of the Newborn Screening Pilot for Sickle Cell Disease in Suriname Using the Non-Adoption, Abandonment, Scale-Up, Spread, and Sustainability (NASSS) Framework.

Ming-Jan Tang, Jimmy Roosblad, John Codrington, Marjolein Peters, Aartie Toekoen, Patrick F van Rheenen, Amadu Juliana

Abstract read
In one paragraph

Article in International journal of neonatal screening, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ming-Jan TangDepartment of Paediatrics, Streekziekenhuis Koningin Beatrix, 7101 BN Winterswijk, The Netherlands.ORCID 0000-0002-1226-536X
Jimmy RoosbladLaboratory Academisch Ziekenhuis, Paramaribo, Suriname.ORCID 0000-0002-6800-8055
John CodringtonLaboratory Academisch Ziekenhuis, Paramaribo, Suriname.
Marjolein PetersDepartment of Paediatric Haematology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Aartie ToekoenAcademic Pediatric Center Suriname, Academic Hospital Paramaribo, Paramaribo, Suriname.
Patrick F van RheenenUniversity of Groningen, University Medical Centre Groningen, Beatrix Children's Hospital, Department of Paediatric Gastroenterology, Hepatology and Nutrition, 9713 GZ Groningen, The Netherlands.ORCID 0000-0003-3867-2665
Amadu JulianaAcademic Pediatric Center Suriname, Academic Hospital Paramaribo, Paramaribo, Suriname.

Funding

Uitvoeringsorganisatie Twinningfaciliteit Suriname-Nederland UTSN2-1-Z-113-G
6 · The paper itself

Abstract

The early detection of sickle cell disease (SCD) is vital to reduce mortality among affected children. Suriname currently lacks a newborn screening programme (NSP) for SCD. We performed a pilot programme to evaluate the scalability of such an initiative. Dried blood spots were collected from five birth centres and subjected to electrophoresis analysis. The programme scalability was evaluated using the non-adoption, abandonment, scale-up, spread, and sustainability framework. Challenges across six domains (illness, technology, value proposition, adopter system, organisation, and societal system), were categorised hierarchically as simple 😊, complicated 😐, or complex 😢. It has been proven that implementing programmes with mainly complicated challenges is difficult and those in mainly complex areas may be unachievable. SCD was detected in 33 of 5185 (0.64%) successfully screened newborns. Most of the domains were classified as simple or complicated. Disease detection and technology suitability for screening in Suriname were confirmed, with favourable parental acceptance. Only minor routine adjustment was required from the medical staff for programme implementation. Complex challenges included a reliance on external suppliers for technical maintenance, ensuring timely access to specialised paediatric care for affected newborns, and securing sustainable financial funding. Scaling up is challenging but feasible, particularly with a targeted focus on identified complex challenges.

Indexed as

abandonmentimplementation researchNASSSnewborn screeningnon-adoptionscale-upSCDsickle cell diseasespread and sustainability frameworkSuriname

Identifiers

PMID39051402
PMCPMC11270170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.